India, May 9 -- Palatin Technologies, Inc. (PTNT), a biopharmaceutical company advancing melanocortin-based therapies, shared new preclinical findings at the 2025 ARVO Annual Meeting.
The results highlight the therapeutic potential of melanocortin agonists PL9654 and PL9655 in treating diabetic retinopathy (DR). These compounds demonstrated strong anti-inflammatory effects, stabilization of the blood-retinal barrier, reduction in VEGF signaling, and protection of retinal ganglion cells-factors central to DR progression.
Both PL9654 and PL9655 showed efficacy across several administration routes, including topical, and in various disease models. The presented data underscore their ability to preserve vision, reduce inflammation, and suppre...